阿法替尼的合成路线图解
作者：涂远彪;王敏;朱五福;
Author：
收稿日期： 年卷（期）页码：2016,31(03):-317-320
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：阿法替尼;酪氨酸激酶抑制剂;抗肿瘤;合成;工业化;合成路线图解
Key words：
基金项目：国家自然科学基金资助项目(批准号:81460527);;
江西省自然科学基金项目(20142BAB215020)
中文摘要
分析阿法替尼(1)及其关键中间体4-[(3-氯-4-氟苯基)氨基]-6-硝基-7-[(S)-(四氢呋喃-3-基)-氧基]-喹唑啉(12)的合成方法,找到适合工业化生产的合成路线。通过中间体12合成阿法替尼的方法工艺简单,成本低,适合工业化生产。
参考文献
[1]US FDA.FDA approves new treatment for a type of late-stage lung cancer[EB/OL][2014-05-12].http://www.Fda.gov/News Events/Newsroom/Press Announcements/ucm360499.htm.
[2]王允芬,宋勇.Afatinib(阿法替尼)治疗非小细胞肺癌的研究进展[J].中华肺部疾病杂志,2012,5(4):364-370.
[3]Himmelsbach I F,Langkope E,Blech S,et al.Quinazoline derivatives,medicaments containing said compounds,their utilization and method for the production thereof[P].WO0250043A1.2002-06-27.
[4]Singer T,Colbatzky F,Platz S.Utilization inhibitors EGFR mediated signal transduction for the treatment benign prostatic hyperplasia(BPH)/prostatic hypertrophy[P].WO03094921A2.2003-11-20.
[5]Schroeder J,Dziewas G,Fachinger T,et al.Process for preparing aminocrotonylamino-substituted quinazoline derivatives[P].WO2007085638A1.2007-08-02.
[6]Zhang X,Peng T,Ji X,et al.Synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor[J].Bioorg Med Chem,2013,21(24):7988-7998.
[7]Pandey A,Volkots DL,Seroogy JM,et al.Identification of orally active,potent,and selective 4-piperazinyl quinazolines as antagonists of the platelet-eerived growth factor receptor tyrosine kinase family[J].J Med Chem,2002,45(17):3772-3793.
[8]Melanie,Reich S,Kuehnert S,et al.Substituted 4-aminoquinazoline compounds with metabotropic glutamate receptor regulating activity and uses thereof[P].US200969320A1,2009-03-12.
[9]Lohmann,Andrew PH,Laurant FA,et al.Substitutend quinazolines[P].US5962458A1.1999-10-05.
[10]Ahn,Keuk CK,Se YL,et al.Quinazoline derivat as a multiplex inhibitor and method for the prepapation thereof[P].WO200755514A1.2007-05-18.
[11]Young CM,Lee K,Jong W,et al.Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1selective inhibitor-resistant non-small cell lung cancer[J].J Med Chem,2009,52(21):6880-6888.
[12]Wu JW,Chen WT,Xia GX,et al.Design,synthesis,and biological evaluation of novel conformationally constrained inhibitors targeting EGFR[J].Bioorg Med Chem Lett,2013,4(10):974-978.
[13]Fakhoury,Stephenal,Helentr.4-Phenylamino-quinazolin-6-yl-amides[P].US2005250761A1.2005-11-10.
[14]Tobe,Masanori,Tomizawa,et al.Novel quinazoline derivatives[P].EP1229025A1.2002-08-07.
[15]Zhou J,Fu LB,Lv M,et al.Copper(I)iodide catalyzed domino process to quinazolin-4(3H)-ones[J].Synthesis,2008,24:3974-3980.
[16]Tanaka,Kazuo S,Takafumi,et al.Mthod for production of quinazolin-4-on derivative[P].EP1997812A1.2008-12-03.
[17]Li JR,Chen X,Shi DX,et al.A new and facile synthesis of quinazoline-2,4(1 H,3H)-diones[J].Org Lett,2009,11(6):1193-1196.
[18]Buha VM,Rana DN,Chhabria MT,et al.Synthesis,biological evaluation and QSAR study of a series of substituted quinazolines as antimicrobial agents[J].Med Chem Res,2013,22(9):4096-4109.
[19]Bridges AJ,Zhou H,Cody DR,et al.Tyrosine kinase inhibitors.8.An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline,a potent inhibitor of the epidermal growth factor receptor[J].J Med Chem,1996,39(1):267-276.
[20]Schnur,Rodney CA,Lee D.Alkynyl and azido-substituted 4-anilinoquinazlines[P].US5747498A1.1998-05-05.
[21]Kitano Y,Kawahara E,Suzuki T,et al.Quinazoline derivatives[P].US2004116422A1.2004-06-17.
[22]许学农.6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法[P].CN103288757.2013-09-11.
[23]许学农.一种阿法替尼的制备方法[P].CN103288808.2013-09-11.
[24]许学农.一种阿法替尼的制备方法[P].CN201310182778.2013-8-14.
[25]许学农.一种阿法替尼的制备方法[P].CN201310173504.2013-8-21.
[26]许学农.一种阿法替尼的制备方法[P].CN201310180796.2013-9-11.
[27]许学农.一种阿法替尼的制备方法[P].CN103254182.2013-08-21.
【关闭】
